According to the new report, single-dose efficacy was 76% for up to 3 months. A full list of ingredients for the qualitative and quantitative composition of … COVID-19 Vaccine AstraZeneca is a vaccine used to protect people aged 18 years and older against COVID-19. AstraZeneca and Johnson & Johnson will both resume their paused coronavirus vaccine trials in the US. to get emergency authorization to distribute its vaccine. Surprisingly, the vaccine combination in which the first dose was only at half strength was 90 percent effective at preventing Covid-19 in the trial. After discovering the error, the researchers gave each affected participant the full strength booster shot as planned about a month later. AstraZeneca is also seeking Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries. The analysis also showed the potential for the vaccine to reduce asymptomatic transmission of the virus, based on weekly swabs obtained from volunteers in the UK trial. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body. EMA’s human medicines committee has thoroughly assessed the data on the quality, safety and efficacy of the vaccine … COV002 is a single-blinded, multi-centre, randomised, controlled Phase II/III trial assessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. Simon Santi – Pool/Getty Images The results were pooled from across the two studies in Britain and Brazil, which have slightly different designs. Article content. EMA has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus disease 2019 (COVID-19) in people from 18 years of age. An adenovirus-based vaccine called Sputnik V is already being distributed in Russia on an emergency basis, although researchers have yet to release detailed results from their late-stage trial. Oxford University has been conducting phase three trials in … The Brazil National Health Surveillance Agency (ANVISA) said it … It might also mean waiting for the first results from the American study, which aren’t expected until next year. Contacts AstraZeneca has reported that it has obtained ‘good data so far’ on its Covid-19 vaccine candidate, which was licensed from the University of Oxford and is currently in large-scale clinical studies. By Robert Preidt HealthDay Reporter. We have answers to many of your questions. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Trials will determine how well the vaccine will protect from the COVID-19 disease and measure safety and immune responses in different age ranges and at various doses. AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Fewer than 2,800 volunteers got the half-strength initial dose, out of the more than 23,000 participants whose results were reported on Monday. A VOLUNTEER in AstraZeneca's clinical trial of the Covid-19 vaccine in Brazil has died. Participants receive one or two intramuscular doses of a half dose (~2.5 x1010 viral particles) or full dose (~5x1010 viral particles) of AZD1222 or comparator, meningococcal vaccine MenACWY. COVID-19 Vaccine AstraZeneca was co-invented by the University of Oxford and its spin-out company, Vaccitech. Europe's coronavirus vaccine rollout has been thrust into the spotlight again after Italy blocked a shipment of Oxford-AstraZeneca vaccines to Australia. In addition to the programme led by Oxford University, AstraZeneca is conducting a large trial in the US and globally. Is it safe to get one during pregnancy. On Monday, AstraZeneca and Oxford released details about the first 131 volunteers to get Covid-19 in late-stage trials in the United Kingdom and Brazil. Please refer to your approved national product label (SmPC) for current product information. A volunteer participating in the AstraZeneca vaccine trial having blood drawn in Oxford, England, last week. COV002 TUESDAY, Dec. 8, 2020 (HealthDay News) -- AstraZeneca's COVID-19 vaccine is safe and effective, new data from late-stage trials shows.. One dosing regimen showed 90% efficacy when a half-dose was followed by a full-dose after at least one month, based on mixed trials with no participants over 55 … A trial volunteer is given the Oxford/AstraZeneca Covid vaccine at the Centre for Clinical Vaccinology and Tropical Medicine, Oxford. The vaccine can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/36-46 degrees Fahrenheit) for at least six months and administered within existing healthcare settings. Veeva ID: Z4-25396Date of next review: August 2022. Eligible Albertans can start making appointments for the AstraZeneca COVID-19 vaccine on Wednesday, and upgrades have been made to the booking system. Outside experts have plenty of unanswered questions. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. AstraZeneca and Oxford have publicly released the protocol documents that serve as a road map for how the trials in the United States and the United Kingdom are evaluating the vaccine. All of the volunteers got two doses about a month apart, but in some cases the first dose was only at half strength. A look at all the vaccines that have reached trials in humans. With 3 months between the two doses, the interval used in the UK, efficacy was 82.4%. Participants had blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. For Media contacts, click here. 467–478). Participants have blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. Participants have blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. Earlier studies show older people, as well as younger people, appear to have an equally strong immune response to the vaccine. The United Kingdom-based global biopharmaceutical company AstraZeneca is leading the trial as regulatory sponsor. COV003 is a single-blinded, multi-centre, randomised, controlled Phase III trial assessing the safety, efficacy, and immunogenicity of AZD1222 in 10,300 participants in Brazil. In addition, extending the dosing interval not only boosts the vaccine’s efficacy, but also enables more people to be vaccinated upfront. Unlike other vaccine trials, which only looked at symptomatic cases of COVID-19, the AstraZeneca/Oxford study also looked at whether their vaccine … COVID-19 vaccines from Pfizer and German partner BioNTech and from Moderna have reported efficacy levels of more than 90 per cent in late stage trials. COV005 He tells Elisabeth Mahase how the Oxford vaccine came to be, how dosing was worked out, and whether it will stand up to the new variants Andrew Pollard was in a French taxi when he realised what was coming. AstraZeneca’s new clinical trial results are positive but confusing, leaving many experts wanting to see more data before passing final judgment on how well the vaccine will work. No one knows. A volunteer taking part in the trial for AstraZeneca’s COVID-19 vaccine, which Australians could be given doses of, has died. The MHRA can confirm that the COVID-19 Vaccine AstraZeneca does not contain any components of animal origin. The researchers speculated that the lower first dose did a better job of mimicking the experience of an infection, promoting a stronger immune response. This month has seen a torrent of news about experimental vaccines to prevent Covid-19, with the latest development from AstraZeneca and the University of Oxford. Published Thu, Nov 26 2020 7:57 AM EST Updated Thu, Nov 26 … But the study data are confusing, scrambled by differences in the time between shots and a manufacturing mix-up that resulted in … Tens of thousands of people around the world are currently participating in clinical trials to test the first COVID-19 vaccine contenders. Although none of those studies have reached the final, so-called Phase 3 trials, they have allowed researchers to examine the safety of the vaccine platform. You are about to access AstraZeneca historic archive material. The AstraZeneca COVID-19 vaccine has already been granted a conditional marketing authorisation or emergency use in close to 50 countries, spanning four continents including in the EU, a number of Latin American countries, India, Morocco and the UK. COVID-19 Vaccine AstraZeneca was co-invented by the University of Oxford and its spin-out company, Vaccitech. AstraZeneca provides this link as a service to website visitors. This website is intended for people seeking information on AstraZeneca's worldwide business. It also helps to support the policy recommendation made by the Joint Committee on Vaccination and Immunisation for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected 22 days after a single dose of the vaccine.”. AstraZeneca pauses COVID-19 vaccine trial after unexplained illness in U.K. By Hannah Jackson Global News Posted September 8, 2020 6:06 pm . Sir Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, said: “This primary analysis reconfirms that our vaccine prevents severe disease and keeps people out of hospital. Lee Brown, New York Post 8 comments Combined results from 4 clinical trials in the United Kingdom, Brazil and South Africa showed that COVID-19 Vaccine AstraZeneca was safe and effective at preventing COVID-19 in people from 18 years of age. Canada's National Advisory Committee on Immunization (NACI) is not recommending the use of AstraZeneca's COVID-19 vaccine in individuals aged 65 … Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. AstraZeneca has published the primary analysis results from the Phase III clinical trials of its Covid-19 vaccine in the UK, Brazil and South Africa, which showed that the vaccine is safe and effective in preventing Covid-19 more than 22 days after the first dose. Researchers in Britain had been meaning to give volunteers the initial dose at full strength, but they made a miscalculation and accidentally gave it at half strength, Reuters reported. For years, Oxford researchers have been testing their chimpanzee adenovirus vaccine, ChAdOx1, on a number of other diseases including Ebola and Zika. Half received the vaccine and half were given a control injection, either a dummy injection or another non-COVID vaccine. In contrast, the combination of two, full-dose shots led to just 62 percent efficacy. But some details have not been made public, such as how many Covid-19 cases will need to turn up in order to prompt the end of the British and Brazilian studies. A VOLUNTEER in AstraZeneca’s clinical trial of the Covid-19 vaccine in Brazil has died. A vial of the AstraZeneca COVID-19 vaccine is pictured at Perth Convention and Exhibition Centre on March 7, 2021 in Perth, Australia. In the spring, AstraZeneca and Oxford started running clinical trials, first in Britain and then in other countries including the United States. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. AstraZeneca plans to start testing the half-strength initial dose in its continuing United States trial and to ask the agency for guidance on how to proceed. Despite a setback in a vaccine trial, the World Health Organization has decided to recommend the use of the AstraZeneca vaccine to protect adults from COVID-19, even in … U.S. health officials have promised that Covid-19 vaccines will be available free of charge to any American who wants one. How many people have been vaccinated in your state? For details on how to contact the Investor Relations Team, please click here. A participant in the South African trial of the AstraZeneca–University of Oxford COVID-19 vaccine has blood drawn before receiving her … That reflects the prices paid by governments like the United States that have placed orders for tens or even hundreds of millions of doses of the vaccine. COV005 is a blinded, multi-centre, randomised, controlled Phase I/II trial assessing the safety, efficacy, and immunogenicity of AZD1222 in 2,070 participants in South Africa. The Brazil National Health Surveillance Agency (ANVISA) said it … AstraZeneca’s vaccine is already available in more than 50 countries after preventing COVID-19 in clinical trials. The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccine known as ChAdOx1 nCoV-19 or AZD1222. It was from the University of Wisconsin Madison doctor who is running UW’s clinical trial of AstraZeneca's COVID-19 vaccine. AstraZeneca’s new clinical trial results are positive but confusing, leaving many experts wanting to see more data before passing final judgment on how well the vaccine will work. AstraZeneca says its trial data suggests it works among over 65s. AstraZeneca Resumes Its COVID-19 Vaccine Trials In The U.K. : Coronavirus Updates The company had placed its worldwide vaccine trials on hold for … This page will be updated as additional information is available. I believe there will be better options. One dosing regimen showed 90% efficacy when a half-dose was followed by a full-dose after at least one month, based on mixed trials with no participants over 55 … The AstraZeneca COVID-19 vaccine is not approved in the … On Tuesday, trials of thee COVID-19 vaccine being developed by Oxford University and AstraZeneca have been placed on a hold after a suspected dangerously bad reaction to the shot. COVID-19 is caused by a virus called coronavirus (SARS CoV 2). On Monday they announced that a preliminary analysis showed their vaccine was effective — especially when the first dose was mistakenly cut in half. Together with the new findings on reduced transmission, we believe this vaccine will have a real impact on the pandemic.”, Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial, and co-author of the paper, said: “These new data provide an important verification of the interim data that has helped regulators such as the MHRA in the UK and elsewhere around the world to grant the vaccine emergency use authorisation. Providers in the U.S. are administering about 2.1 million doses of Covid-19 vaccines per day, on average. The human cells then produce the protein and train the immune system to marshal antibodies and T-cells against it without causing disease. Currently available clinical trial data do not allow an estimate of vaccine … Alaska becomes the first state to open vaccine eligibility to all residents or workers 16 and older. Marshall said she had a 66% chance of getting the real vaccine during the AstraZeneca trial. The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, is a COVID-19 vaccine developed by Oxford University and AstraZeneca given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19). Marshall said she had a 66% chance of getting the real vaccine during the AstraZeneca trial. She will undergo observations for between 12-18 months. The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended this week after an illness in a study subject in Britain, casting … Collecting more data might mean waiting for more results from participants in Britain who got the half dose. We encourage you to read the privacy policy of every website you visit. Andrew Pollard has been leading the Oxford vaccine clinical trials in the UK, Brazil, and South Africa. AstraZeneca’s COVID-19 vaccine has not yet been submitted for U.S. approval. On Tuesday, trials of thee COVID-19 vaccine being developed by Oxford University and AstraZeneca have been placed on a hold after a suspected dangerously bad reaction to the shot. It is not yet clear whether the results announced on Monday are enough for AstraZeneca to take the first formal step of the regulatory process: submitting an application to the F.D.A. A Brazilian volunteer in the AstraZeneca COVID-19 vaccine trial has died, health officials announced Wednesday. Although the announcement gave efficacy rates, it left out details that would have helped outside researchers independently assess the data: It did not say how many cases of Covid-19 were found in the group that got the half-strength initial dose, or in the group that got the regular-strength initial dose, or in the group that got a placebo. Nova Scotia will be receiving 13,000 doses of the AstraZeneca COVID-19 vaccine next week. “The only thing that you can really say right now is that the vaccine seems to work,” Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai in New York City. The researchers have not found any serious side effects. Coronavirus AstraZeneca vaccine: Volunteer dies during human trials. … On Monday, AstraZeneca and Oxford released details about the first 131 volunteers to get Covid-19 in late-stage trials in the United Kingdom and Brazil. The primary analysis for efficacy was based on 17,177 participants accruing 332 symptomatic cases from the Phase III UK (COV002), Brazil (COV003) and South Africa (COV005) trials led by Oxford University and AstraZeneca, a further 201 cases than previously reported. (2020) Lancet, 396(10249), pp. In parallel, AstraZeneca continues to fulfil its commitment for broad and equitable access to the vaccine, should late-stage clinical trials prove successful. When the researchers adapted ChAdOx1 for Covid-19, their early clinical trials also did not turn up any adverse reactions. COVID vaccine causes tensions in Europe 02:20. The AstraZeneca-Oxford vaccine uses a weakened common cold virus to carry SARS-CoV-2 genetic material into cells to make coronavirus spike proteins that trigger an immune response. South African health officials said Sunday they're pausing the country's rollout of AstraZeneca's coronavirus vaccine after a study showed it offered reduced protection from the Covid … Participants are randomised to receive two intramuscular doses of a full dose (~5x1010 viral particles) of AZD1222 or comparator, meningococcal vaccine MenACWY as first dose and a saline placebo as second dose. Coronavirus AstraZeneca vaccine: Volunteer dies during human trials. A volunteer taking part in the trial for AstraZeneca’s COVID-19 vaccine, which Australians could be given doses of, has died. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. The announcement came on the heels of stunning reports from Moderna, as well as Pfizer and BioNTech. Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. The Oxford-AstraZeneca vaccine for Covid-19 is more rugged than the mRNA vaccines from Pfizer and Moderna. It was a lucky mistake. A new trial is to test how well the Oxford-AstraZeneca coronavirus vaccine works in children. Adenovirus-based vaccines are also being tested by Johnson & Johnson, as well as by labs in China, Italy and elsewhere. Experts have had a hard time parsing the results because of the way they were announced. AstraZeneca Such holds are not uncommon, and it’s not clear yet how long AstraZeneca’s will last. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR. In Phase 3 trials, however, the testing had to be paused twice when volunteers experienced neurological problems. The group responsible for determining the rollout of the COVID-19 vaccine in Manitoba has made plans for who will receive the AstraZeneca COVID-19 vaccine once it arrives in the province. These studies involved around 24,000 people altogether. Clinical trials suggested that the AstraZeneca formula was between 60% and 90% effective at preventing symptomatic COVID … Important notice for users In total, Oxford University and AstraZeneca expect to enrol up to 60,000 participants globally. “It’s just hard to say how well it works compared to others.”. It's the third shot to be approved for use by Health Canada. This is the third COVID-19 vaccine that EMA has recommended for authorisation. I, along with 460 volunteers, had … COVID-19 Vaccine AstraZeneca, formerly AZD1222 Severe obesity raises the risk of Covid-19 hospitalization and death, a study finds. AstraZeneca Hopes New Data Gets Its Covid Vaccine Back on Track The results of large-scale U.S. trials, expected soon, will either clear up or compound the … T he participant who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with … When can you get the vaccine? The data showed that PCR positive readings were reduced by 67% (CI: 49%, 78%) after a single dose, and 50% (CI: 38% to 59%) after the two dose regimen, supporting a substantial impact on transmission of the virus. AstraZeneca is not responsible for the privacy policy of any third party websites. What are the vaccine’s side effects? Clinical trials … Trial participants are aged 18-65 years, who are living with or without HIV, are randomised to receive two intramuscular doses of AZD1222 at 5-7.5 x1010 viral particles or saline placebo. A new trial is to test how well the Oxford-AstraZeneca coronavirus vaccine works in children. AstraZeneca’s ‘mistake’ in COVID-19 vaccine trials could halt approval One of the world’s leading coronavirus vaccine contenders has hit a major stumbling block after researchers revealed a serious error. What We Know About AstraZeneca’s Head-Scratching Vaccine Results. The Oxford/AstraZeneca vaccine is considered the leading candidate in the race to develop an effective COVID-19 vaccine. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR. AstraZeneca’s vaccine has a number of advantages over other leading vaccine candidates: It’s easier to mass produce and store, and it’s also cheaper, at $3 to $4 per dose. Los Angeles schools and teachers’ union agreed to reopen classrooms. Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine and a related shot by the Serum Institute of India for use around the country with the first doses expected to arrive soon. But AstraZeneca’s news was murkier, leaving many experts wanting to see more data before passing final judgment on how effective the vaccine may turn out to be. All … Health Canada has approved its third COVID-19 vaccine, authorizing the jab made by AstraZeneca and Oxford University after a lengthy review of clinical trial details. The Food and Drug Administration did not directly tie the vaccine to the problems, but when the agency allowed the trial to resume in the United States, it advised the company to be vigilant for any signs of similar problems. Our country sites can be located in the AZ Network. Like the results from Pfizer and Moderna, the data on AstraZeneca’s vaccine was summarized in a news release. A Brazilian volunteer in the AstraZeneca COVID-19 vaccine trial has died, health officials announced Wednesday. Scientists have been testing adenovirus-based vaccines for decades, but it wasn’t until July of this year that the first one was licensed, when Johnson & Johnson got approval from European regulators for an Ebola vaccine. On Friday, British regulators said they had received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine is effective in the elderly. The Oxford and AstraZeneca vaccine uses a chimpanzee adenovirus viral vector to trigger expression of the characteristic spike protein of SARS-CoV-2, the virus that causes COVID-19, in humans. The Oxford/AstraZeneca Covid vaccine has efficacy of 90% in a small group who got a half-dose first, but only 62% in the majority, full trial data … On 15 August, safety and immunogenicity data from the Phase I / II AZD1222 trial was published in The Lancet (Folegatti, P, et al. The first round of trials showed that the vaccine prompted volunteers to produce antibodies against the coronavirus — a good sign. I have read this warning and will not be using any of the contained product information for clinical purposes. In addition, weekly swabbing are done for detection of infection and assessment of vaccine efficacy against infection. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. By Robert Preidt HealthDay Reporter. TUESDAY, Dec. 8, 2020 (HealthDay News) -- AstraZeneca's COVID-19 vaccine is safe and effective, new data from late-stage trials shows.. The potential vaccine has entered its final trial in Brazil, with studies ongoing in the UK and South Africa. They genetically altered the virus so that it carried a gene for a coronavirus protein, which would theoretically train a person’s immune system to recognize the real coronavirus. That’s a pretty small number of participants on which to base the spectacular efficacy results — far fewer than in Pfizer’s and Moderna’s trials. The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose. More clinical trial data on AstraZeneca's vaccine is also expected in the coming weeks from the U.S. NACI's recommendations also include that the Pfizer-BioNTech vaccine … Austria suspends AstraZeneca COVID-19 vaccine batch after death Back to video One 49-year-old woman died as a result of severe coagulation disorders, while a … AstraZeneca Phase I / II Covid-19 vaccine trial underpowered to demonstrate protection. But other factors, like the size and makeup of the groups that got different doses, may also be at play. AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S. One of them, made by the drug company Pfizer, was just authorized by the FDA last week, setting off a historic effort to vaccinate the majority of Americans to stop the spread of the coronavirus. It also did not say how many severe cases were found in the placebo group. AstraZeneca’s is the first Phase 3 Covid-19 vaccine trial known to have been put on hold. Regular COVID-19 PCR testing is performed up to one year post-vaccination. Researchers at the University of Oxford built the vaccine using a kind of virus, called an adenovirus, that typically causes colds in chimpanzees. The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, is a COVID-19 vaccine developed by Oxford University and AstraZeneca given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. The AstraZeneca COVID-19 vaccine is not approved in the … In their announcement on Monday, AstraZeneca and Oxford said that no serious safety issues were confirmed related to the vaccine. vaccines, vaccination with COVID-19 Vaccine AstraZeneca may not protect all vaccine recipients (see section 5.1). Results demonstrated vaccine efficacy of 76% (CI: 59% to 86%) after a first dose, with protection maintained to the second dose. AstraZeneca says its trial data suggests it works among over 65s. While the push is on to get more of the COVID-19 vaccine, there is some hope on the horizon as both Johnson & Johnson and AstraZeneca are nearing the end of their vaccine trials. Read our COVID-19 research and news. DNA is not as fragile as RNA, … The agency is likely to advise the company to collect more data on its promising dosing plan before submitting a formal application to authorization, several vaccine experts said. With an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82% (CI: 63%, 92%). Dr João Pedro Feitosa died from complications from the coronavirus while taking part in the testing of … AstraZeneca COVID-19 vaccine; Novavax COVID-19 vaccine Learn more about U.S. COVID-19 vaccine clinical trials, including vaccines in earlier stages of development, by visiting clinicaltrials.gov external icon. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. As the world awaits the roll-out of a vaccine to combat coronavirus, the announcement of AstraZeneca’s trial results this week was greeted with enthusiasm by some and scepticism by others.